Stocks · News reference
Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.65) by 69.23 percent. This is a 84.96 percent increase over losses of $(1.33) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Assembly Biosciences Announces Exercise Of Option To Share 40% Of U.S. Development Costs And Profits For Gilead-Partnered HSV Helicase-Primase Inhibitor Program In Recurrent Genital Herpes
Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45
HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.